Tarsus Pharmaceuticals (TARS) said late Wednesday it has priced an upsized underwritten public offering of 2.8 million shares at $44.50 per share for gross proceeds of about $125 million.
Underwriters have been granted a 30-day option to purchase up to 421,348 additional shares.
The offering, which was upsized from the initial $100 million, is set to close Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.